Mounjaro is Eli Lilly's FDA-approved tirzepatide, made in a factory and approved for type 2 diabetes. Compounded tirzepatide is made to order by a state-licensed 503A pharmacy under a prescription, and it is not FDA approved. Both use tirzepatide as the active ingredient, but they differ in who makes them, who checks them, what the label says, what they cost, and what evidence stands behind them. Start with our tirzepatide guide if you are new to the drug.
Key takeaways
- Mounjaro was approved by the FDA on May 13, 2022 (NDA 215866) to improve blood sugar in adults with type 2 diabetes. Zepbound, the same molecule, is approved for weight management and sleep apnea.
- Compounded tirzepatide is not FDA approved and is not interchangeable with Mounjaro or Zepbound. The FDA does not check it for safety, effectiveness or quality before sale.
- Every tirzepatide trial in our verified list tested the branded product. There is no trial of a compounded product, so "is compounded as effective" has no published answer.
- FormBlends compounded tirzepatide is $149 for the first month and $239 a month after, at any dose. Zepbound self-pay vials run $299 to $699 a month by dose; we do not print a Mounjaro price because it is not in our verified sources.
- A licensed clinician decides whether compounded tirzepatide is appropriate for you.
Compounded tirzepatide vs Mounjaro: the comparison table
| Feature | Mounjaro | Compounded tirzepatide |
|---|---|---|
| Active ingredient | Tirzepatide | Tirzepatide, per the pharmacy label; some products add B12 or niacinamide |
| Who makes it | Eli Lilly, under an FDA-approved application | A state-licensed 503A compounding pharmacy, for one named patient |
| FDA status | FDA approved, NDA 215866 | Not FDA approved; not reviewed for safety, effectiveness or quality |
| Approved use | Type 2 diabetes, with diet and exercise | None; the prescriber decides the use |
| Oversight | FDA | State board of pharmacy |
| Form | Prefilled pen or single-dose vial, 2.5 to 15 mg | Usually a multi-dose vial; dose drawn with an insulin syringe |
| Dose schedule | 2.5 mg weekly for 4 weeks, then 2.5 mg steps every 4 or more weeks, up to 15 mg | Set by the prescriber; the label schedule is the usual reference |
| Storage | 2 to 8 C; up to 21 days at up to 30 C; do not freeze | Per the pharmacy label |
| Trial evidence | SURPASS-1 through SURPASS-5; the molecule also has SURMOUNT data | None for the compounded product |
| Monthly cost | Not printed here (no verified price in our sources); Zepbound self-pay is $299 to $699 | FormBlends: $149 first month, then $239, or $214 with Subscribe & Save |
Source: Mounjaro and Zepbound prescribing information (DailyMed); FDA, Compounding and the FDA: Questions and Answers; FormBlends pricing page; LillyDirect self-pay pricing.
What "same active ingredient" does and does not mean
Tirzepatide is a specific 39-amino-acid peptide. When a licensed pharmacy compounds it correctly from a tested ingredient, the molecule in the vial is tirzepatide. That is the reason compounded products exist and the reason people compare them with Mounjaro. It is not the same as saying the products are equivalent. Mounjaro's label, dosing, purity, sterility and stability were reviewed by the FDA and are backed by the SURPASS trials. A compounded vial's purity, sterility and stability rest on the pharmacy that made it, and no trial has tested it. The FDA's page on unapproved GLP-1 drugs makes this point directly: compounded versions are not evaluated by the agency and may differ from the approved drug, including in the form of the active ingredient used.
Get compounded tirzepatide, first month $149, then $239 per month, or $214 per month with Subscribe & Save
Free provider review, personalized dosing, and ongoing support included.
Start Free Assessment →Is compounded tirzepatide as effective as Zepbound or Mounjaro?
There is no published head-to-head trial in our sources, so no one can answer this with data. What exists is the evidence for the branded product, which is what people are really asking about.
| Trial (branded tirzepatide) | Population | Result | Comparator |
|---|---|---|---|
| SURPASS-1, 40 weeks | Type 2 diabetes, monotherapy | A1c -1.87, -1.89, -2.07 points (5, 10, 15 mg) | +0.04 placebo |
| SURPASS-2, 40 weeks | Type 2 diabetes | A1c -2.01 to -2.30; weight -7.6 to -11.2 kg | Semaglutide 1 mg: A1c -1.86; weight -5.7 kg |
| SURPASS-3, 52 weeks | Type 2 diabetes | A1c -1.93 to -2.37 | Insulin degludec: -1.34 |
| SURMOUNT-1, 72 weeks | Obesity or overweight, no diabetes | Weight -15.0%, -19.5%, -20.9% (5, 10, 15 mg) | -3.1% placebo |
| SURMOUNT-2, 72 weeks | Obesity with type 2 diabetes | Weight -12.8% (10 mg), -14.7% (15 mg) | -3.2% placebo |
Source: PubMed entries for SURPASS-1 (34186022), SURPASS-2 (34170647), SURPASS-3 (34370970), SURMOUNT-1 (35658024) and SURMOUNT-2 (37385275).
A compounded vial that contains the right amount of tirzepatide, injected on the same schedule, should act on the same receptors. Whether it does in practice depends on the pharmacy, which is why the licensing checks on our is compounded tirzepatide safe page matter more than any marketing claim.
Compound tirzepatide reviews: how to read them
Reviews of compounded tirzepatide mix three things: the service (shipping, support, price), the experience of the molecule (appetite, nausea, weight), and the pharmacy (how the vial looked, whether it was cold on arrival). Only the middle one relates to effectiveness, and it is the least reliable, because a single person's weight change cannot be separated from diet, placebo effect or normal variation. In SURMOUNT-1, the placebo group lost 3.1% of body weight over 72 weeks with no active drug. This page does not print reviews, ratings or testimonials, and you should be wary of pages that lean on them instead of the trial record.
Cost: where the difference is biggest
Our verified sources include Lilly's published self-pay prices for Zepbound vials but not a Mounjaro price, so the honest comparison is compounded tirzepatide against Zepbound self-pay, which is the same molecule at Lilly's cash price.
| Option | Monthly cost |
|---|---|
| FormBlends compounded tirzepatide, first month | $149 |
| FormBlends compounded tirzepatide, ongoing | $239 ($214 with Subscribe & Save) |
| Zepbound vial 2.5 mg, LillyDirect self-pay | $299 |
| Zepbound vial 5 mg, LillyDirect self-pay | $399 |
| Zepbound vial 7.5 mg, LillyDirect self-pay | $499 |
| Zepbound vial 10, 12.5 or 15 mg, LillyDirect self-pay | $699 |
| Zepbound with commercial insurance and savings card | As low as $25 |
Source: FormBlends pricing page (verified September 5, 2026); Eli Lilly LillyDirect self-pay pricing (accessed September 4, 2026).
If you have commercial insurance that covers Zepbound or Mounjaro, the branded product with a savings card is usually the cheapest and is FDA approved. If you do not, the FormBlends price is flat at every dose while Zepbound self-pay climbs with the dose. Our tirzepatide cost guide works through the year-long math.
What this means for compounded tirzepatide
FormBlends does not sell Mounjaro. It offers compounded tirzepatide prescribed by independent, state-licensed clinicians of Recess MD LLC and prepared by state-licensed 503A compounding pharmacies (Greenwich RX in Texas, The DrugStore on East State in Ohio, and Chemistry Rx in Pennsylvania), shipped cold with injection supplies included. Compounded tirzepatide is not FDA approved and is not interchangeable with Mounjaro or Zepbound; a licensed provider decides whether it is appropriate for you. See pricing or begin the assessment, where availability for your address is confirmed before any charge.
Frequently Asked Questions
What is the difference between compounded tirzepatide and Mounjaro?
Mounjaro is Lilly's product, approved by the FDA, made under an approved application and backed by the SURPASS trials. Compounded tirzepatide is pharmacy-made for one patient, is not FDA approved, is not reviewed for safety or quality, and has no trials of its own. They share an active ingredient name, not a regulatory status.
Is compounded tirzepatide as effective as Zepbound?
No published head-to-head trial exists in our sources, so there is no data answer. The branded product's results, such as -20.9% mean weight change at 15 mg over 72 weeks in SURMOUNT-1, apply to the tested product only.
Are compound tirzepatide reviews reliable?
They are useful for judging a service's shipping and support, and useless for judging whether the drug works, because one person's weight change cannot be separated from diet or placebo effect. Rely on the trial record for effectiveness and on licensing checks for the pharmacy.
Can I switch between Mounjaro and compounded tirzepatide?
Only with your prescriber. The products are not interchangeable, and the concentration and additives in a compounded vial differ from a Mounjaro pen. Never switch products or doses on your own.
Why is there no Mounjaro price on this page?
Because the only brand prices in our verified sources are Lilly's self-pay prices for Zepbound vials and the $25 savings-card floor. Mounjaro is the same molecule, so those Zepbound figures are the closest verified comparison.
Sources
- Mounjaro prescribing information, DailyMed, revised 08/2026.
- Zepbound prescribing information, DailyMed, revised 08/2026.
- Compounding and the FDA: Questions and Answers, U.S. Food and Drug Administration.
- FDA's Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration.
- Efficacy and safety of a novel dual GIP and GLP-1 receptor agonist tirzepatide in patients with type 2 diabetes (SURPASS-1), Rosenstock et al., Lancet, 2021.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2), Frias et al., New England Journal of Medicine, 2021.
- Once-weekly tirzepatide versus once-daily insulin degludec in type 2 diabetes (SURPASS-3), Ludvik et al., Lancet, 2021.
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1), Jastreboff et al., New England Journal of Medicine, 2022.
Next steps
For the full picture of the compounded option, read the compounded tirzepatide guide, and for the brand-versus-brand question, tirzepatide vs Zepbound. Browse the tirzepatide hub for every other tirzepatide question. Talk to a licensed clinician before starting or changing any medication. Compounded tirzepatide is not FDA approved and is not interchangeable with Zepbound or Mounjaro; a licensed provider decides whether it is appropriate for you.
See your options in about 2 minutes
Take the free quiz and see what fits you. Quick, private, and no commitment to continue.
See my options →